PCSK9 Inhibitors

Agents that inhibit Proprotein Convertase Subtilisin/Kexin Type 9 (see PROPROTEIN CONVERTASE 9 (PCSK9)), an enzyme that plays an important role in the degradation of the LDL receptors. It favors LDL catabolism and reduces plasma LDL-cholesterol (LDL_C) level.

Year introduced: 2022

PubMed search builder options

Subheadings:

Restrict to MeSH Major Topic.

Do not include MeSH terms found below this term in the MeSH hierarchy.

Tree Number(s): D27.505.519.186.071.202.685, D27.505.519.389.745.800.506, D27.505.954.557.500.202.685

MeSH Unique ID: D000091362

Entry Terms:

• PCSK9 Inhibitors, Cardiovascular
• Cardiovascular PCSK9 Inhibitors
• Inhibitors, Cardiovascular PCSK9
• PCSK9 Inhibitors Cardiovascular
• Cardiovascular, PCSK9 Inhibitors

Previous Indexing:

• Anticholesteremic Agents (2018-2021)

All MeSH Categories
Chemicals and Drugs Category
Chemical Actions and Uses
Pharmacologic Actions
Molecular Mechanisms of Pharmacological Action
Antimetabolites
Hypolipidemic Agents
Anticholesteremic Agents
PCSK9 Inhibitors

All MeSH Categories
Chemicals and Drugs Category
Chemical Actions and Uses
Pharmacologic Actions
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Protease Inhibitors
Serine Proteinase Inhibitors
PCSK9 Inhibitors

All MeSH Categories
Chemicals and Drugs Category
Chemical Actions and Uses
Pharmacologic Actions
Therapeutic Uses
Lipid Regulating Agents
Hypolipidemic Agents
Anticholesteremic Agents
PCSK9 Inhibitors